NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=136016&from=4CLASS PERIOD: February 3, 2022 to Febru ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. due to allegations of misleading statements regarding the demand for Gardasil in China, which may have led to inflated stock prices [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Merck from February 3, 2022, to February 3, 2025, to discuss their legal options [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Merck [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck and its executives violated federal securities laws by making false statements about the expected revenue of $11 billion from Gardasil sales by 2030 [4]. - It is claimed that Merck misled investors about the demand for Gardasil in China, leading to an inflated inventory with its distributor, Zhifei [4]. - Following the announcement of a 3% decline in Gardasil sales to $8.6 billion and a temporary pause in shipments to China, Merck's stock price fell by $9.05, or 9.1%, to close at $90.74 per share on February 4, 2025 [5][6].

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submissio ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Merck (MRK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Merck currently has an average brokerage recommendation (ABR) of 1. ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=135486&from=4CLASS PERIOD: February 3, 2022 to Febru ...

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submissio ...

Core Viewpoint - The article emphasizes the importance of defensive stocks in the current global trade tensions, highlighting companies that are expected to maintain stability and growth potential during market volatility [2]. Group 1: Merck (NYSE: MRK) - Merck is a global pharmaceutical giant known for its innovative medical solutions, with a product range that includes cutting-edge cancer drugs, vaccines, and prescription medications [5]. - The company exhibits strong defensive characteristics with a low beta coefficient of 0.36, a high dividend yield of 3.48%, and an impressive return on equity (ROE) of 40.8% [6]. - Current stock price is $94, significantly undervalued compared to a fair value estimate of $121.83, indicating a potential upside of 29.6% [6]. - Analysts have a strong buy rating for Merck, with target prices ranging from $95 to $146, averaging $112.78 [6]. Group 2: NextEra Energy (NYSE: NEE) - NextEra Energy is a leading utility company in the renewable energy sector, employing a strategy that combines traditional and clean energy sources [12]. - The company has a beta value of 0.57, a dividend yield of 3.2%, and operates in a regulated environment, making it less susceptible to trade disputes [13]. - Current stock price is $70.01, with analysts projecting a potential increase of 20%, as target prices range from $52 to $103, averaging $84.27 [13]. - NextEra's strong cash flow and commitment to sustainable development position it as a stable investment during turbulent market conditions [14]. Group 3: Tyson Foods (NYSE: TSN) - Tyson Foods is a major player in the food processing industry, offering a wide range of meat products including beef, pork, and poultry [18]. - The company has defensive traits with a beta value of 0.71, a dividend yield of 3.3%, and a dominant market position in various meat product categories [19]. - Current stock price is $60.53, with a fair value estimate of $75.83, suggesting a potential upside of nearly 25% [19]. - Analysts have a buy rating for Tyson, with target prices ranging from $58 to $80, reflecting its strong position in the supply chain and limited exposure to trade conflicts [20].

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=134604&from=4 CLASS PERIOD: February 3, 2022 to Febr ...

Core Viewpoint - Merck Group reported a recovery in profit growth for 2024, driven by strong performance in healthcare, life sciences, and electronics businesses, achieving full-year expectations [1][2] Group 1: Financial Performance - In 2024, Merck Group's net sales reached €21.2 billion (approximately ¥166.7 billion), with an organic growth of 2.0% [1] - EBITDA is projected to increase to €6.1 billion (approximately ¥48 billion), with an organic growth of 6.9% [1] - By business segment, life sciences net sales were €8.9 billion (approximately ¥70 billion), a year-on-year decline of 3.3%; healthcare net sales were approximately €8.5 billion (approximately ¥66.9 billion), a year-on-year increase of 7.0%; electronics net sales were approximately €3.8 billion (approximately ¥29.9 billion), a year-on-year increase of 4.6% [1] Group 2: Business Segment Insights - The growth in the electronics business was primarily driven by semiconductor solutions, with demand for semiconductor materials increasing due to widespread applications of artificial intelligence [1] - Sales in the semiconductor solutions segment rose to €2.6 billion (approximately ¥20.4 billion), with an organic growth of 7.8% [1] - Display solutions and surface solutions segments reported sales of €748 million (approximately ¥5.88 billion) and €406 million (approximately ¥3.19 billion), respectively [1] Group 3: Future Outlook - For 2025, Merck expects net sales to be between €21.5 billion and €22.9 billion (approximately ¥169.1 billion to ¥180.1 billion) [2] - EBITDA is forecasted to be between €6.1 billion and €6.6 billion (approximately ¥48 billion to ¥51.9 billion) [2]

Investment Rating - The investment rating for the pharmaceutical industry is "Outperform the Market" (maintained) [1] Core Insights - The main growth driver remains the launch of innovative products, particularly in the GLP-1 category, with significant revenue increases reported by companies like Eli Lilly and Novo Nordisk [3] - The report highlights the strong performance of key products across various therapeutic areas, including oncology, metabolism, and immunology, with notable sales growth percentages [3] Summary by Sections 01 Overview of Overseas Pharmaceutical Companies Q4 2024 and Annual Performance - Eli Lilly's revenue increased by 32% in 2024, driven by GLP-1 products [3] - Novo Nordisk's sales reached approximately $40.5 billion, a 25% increase, with significant contributions from GLP-1 products [29] - AstraZeneca and Merck also reported strong growth, with revenue increases of 21% and 10% respectively [3] 02 Performance Review of Overseas Pharmaceutical Companies - Eli Lilly's Q4 sales reached $13.5 billion, a 45% increase, with GLP-1 products contributing significantly [18] - Novo Nordisk's GLP-1 products achieved sales of approximately $22.5 billion, with a 20% increase in the diabetes segment [29] - JNJ's pharmaceutical segment reported $14.3 billion in Q4, with oncology products driving growth [40] R&D Investment - The top 15 pharmaceutical companies invested over $150 billion in R&D in 2024, a 7% increase year-on-year, with a research expense ratio of 21.8% [8] Sales Performance in China - Seven overseas pharmaceutical companies reported combined sales of approximately 515 billion RMB in Q4 2024, with a year-on-year growth of 10% [14]